These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17563301)

  • 1. Clinical research observations with use of exubera in patients with type 1 and 2 diabetes.
    Cefalu WT; Wang ZQ
    Diabetes Technol Ther; 2007 Jun; 9 Suppl 1():S28-40. PubMed ID: 17563301
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-dose rosiglitazone in patients with type 2 diabetes mellitus requiring insulin therapy.
    Lopez CA; Kanna B
    Arch Intern Med; 2008 Mar; 168(5):548. PubMed ID: 18332304
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhaled insulin (exubera).
    Med Lett Drugs Ther; 2006 Jul; 48(1239):57-8. PubMed ID: 16841019
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial.
    Fineberg SE; Kawabata T; Finco-Kent D; Liu C; Krasner A
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3287-94. PubMed ID: 15741258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin antibodies with pulmonary delivery of insulin.
    Fineberg SE; Kawabata TT; Krasner AS; Fineberg NS
    Diabetes Technol Ther; 2007 Jun; 9 Suppl 1():S102-10. PubMed ID: 17563298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An assessment of eligibility for inhaled insulin (Exubera): the Fremantle Diabetes Study.
    Davis TM; Davis WA
    Diabetes Care; 2007 Feb; 30(2):360-1. PubMed ID: 17259508
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial.
    DeFronzo RA; Bergenstal RM; Cefalu WT; Pullman J; Lerman S; Bode BW; Phillips LS;
    Diabetes Care; 2005 Aug; 28(8):1922-8. PubMed ID: 16043733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future prospect of insulin inhalation for diabetic patients: The case of Afrezza versus Exubera.
    Al-Tabakha MM
    J Control Release; 2015 Oct; 215():25-38. PubMed ID: 26222134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes.
    Tran MT; Navar MD; Davidson MB
    Diabetes Care; 2006 Jun; 29(6):1395-6. PubMed ID: 16732030
    [No Abstract]   [Full Text] [Related]  

  • 10. Arguments against the use of inhaled insulin.
    Hirsch IB
    Diabetes Technol Ther; 2007 Jun; 9 Suppl 1():S111-4. PubMed ID: 17563299
    [No Abstract]   [Full Text] [Related]  

  • 11. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus.
    Ceglia L; Lau J; Pittas AG
    Ann Intern Med; 2006 Nov; 145(9):665-75. PubMed ID: 17088580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes.
    Hollander P; Yu D; Chou HS
    Arch Intern Med; 2007 Jun; 167(12):1284-90. PubMed ID: 17592102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled insulin for diabetes mellitus.
    McMahon GT; Arky RA
    N Engl J Med; 2007 Feb; 356(5):497-502. PubMed ID: 17267909
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes.
    Rosenstock J; Cappelleri JC; Bolinder B; Gerber RA
    Diabetes Care; 2004 Jun; 27(6):1318-23. PubMed ID: 15161782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.
    Shearer AT; Bagust A; Liebl A; Schoeffski O; Goertz A
    Pharmacoeconomics; 2006; 24 Suppl 1():35-48. PubMed ID: 16800161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial.
    Rosenstock J; Zinman B; Murphy LJ; Clement SC; Moore P; Bowering CK; Hendler R; Lan SP; Cefalu WT
    Ann Intern Med; 2005 Oct; 143(8):549-58. PubMed ID: 16230721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
    Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
    [No Abstract]   [Full Text] [Related]  

  • 19. Developing a pulmonary insulin delivery system for patients with diabetes.
    Dailey G
    Clin Ther; 2007 Jun; 29(6 Pt 1):1271-83. PubMed ID: 18036389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1-year randomized clinical trial.
    Ko GT; Tsang PC; Wai HP; Kan EC; Chan HC
    Adv Ther; 2006; 23(5):799-808. PubMed ID: 17142216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.